GM-CSF as a therapeutic target in autoimmune diseases
Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been known as a hematopoietic growth factor and immune modulator. Recent studies revealed that GM-CSF also had pro-inflammatory functions and contributed to the pathogenicity of Th17 cells in the development of Th17-mediated autoimmune di...
Gespeichert in:
| Veröffentlicht in: | Inflammation and Regeneration 2016-01, Vol.36 (1), p.8-8, Article 8 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 8 |
|---|---|
| container_issue | 1 |
| container_start_page | 8 |
| container_title | Inflammation and Regeneration |
| container_volume | 36 |
| creator | Shiomi, Aoi Usui, Takashi Mimori, Tsuneyo |
| description | Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been known as a hematopoietic growth factor and immune modulator. Recent studies revealed that GM-CSF also had pro-inflammatory functions and contributed to the pathogenicity of Th17 cells in the development of Th17-mediated autoimmune diseases. GM-CSF inhibition in some animal models of autoimmune diseases showed significant beneficial effects. Therefore, several agents targeting GM-CSF are being developed and are expected to be a useful strategy for the treatment of autoimmune diseases. Particularly, in clinical trials for rheumatoid arthritis (RA) patients, GM-CSF inhibition showed rapid and significant efficacy with no serious side effects. This article summarizes recent findings of GM-CSF and information of clinical trials targeting GM-CSF in autoimmune diseases. |
| doi_str_mv | 10.1186/s41232-016-0014-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5725926</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1979175480</sourcerecordid><originalsourceid>FETCH-LOGICAL-c517t-52d2d2480eaae2f3067d2849617d0695272160afd32c4cae6ed5192133b9d61d3</originalsourceid><addsrcrecordid>eNpdkVFLwzAUhYMoTuZ-gC9S8MWXaG7aJM2LIMNNYeKD-hyy5nbrWNuZtIL_3ozNoSYPuZBzD-fwEXIB7AYgl7chA55yykBSxiCj4oicQZ4zmoNmx_tZS50OyCiEFYtHSCFAn5IB11xomcMZEdNnOn6dJDYkNumW6O0G-64qks76BXZJ1SS279qqrvsGE1cFtAHDOTkp7TrgaP8Oyfvk4W38SGcv06fx_YwWAlRHBXfxZjlDa5GXKZPK8TzTEpRjUguuOEhmS5fyIissSnQxH4c0nWsnwaVDcrfz3fTzGl2BTeft2mx8VVv_ZVpbmb8_TbU0i_bTCBULchkNrvcGvv3oMXSmrkKB67VtsO2DAa00KBEjRunVP-mq7X0T6xkuMiWUAoCogp2q8G0IHstDGGBmy8XsuJjIxWy5GBF3Ln-3OGz8UEi_Af-rhoE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2547577111</pqid></control><display><type>article</type><title>GM-CSF as a therapeutic target in autoimmune diseases</title><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Shiomi, Aoi ; Usui, Takashi ; Mimori, Tsuneyo</creator><creatorcontrib>Shiomi, Aoi ; Usui, Takashi ; Mimori, Tsuneyo</creatorcontrib><description>Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been known as a hematopoietic growth factor and immune modulator. Recent studies revealed that GM-CSF also had pro-inflammatory functions and contributed to the pathogenicity of Th17 cells in the development of Th17-mediated autoimmune diseases. GM-CSF inhibition in some animal models of autoimmune diseases showed significant beneficial effects. Therefore, several agents targeting GM-CSF are being developed and are expected to be a useful strategy for the treatment of autoimmune diseases. Particularly, in clinical trials for rheumatoid arthritis (RA) patients, GM-CSF inhibition showed rapid and significant efficacy with no serious side effects. This article summarizes recent findings of GM-CSF and information of clinical trials targeting GM-CSF in autoimmune diseases.</description><identifier>ISSN: 1880-9693</identifier><identifier>ISSN: 1880-8190</identifier><identifier>EISSN: 1880-8190</identifier><identifier>DOI: 10.1186/s41232-016-0014-5</identifier><identifier>PMID: 29259681</identifier><language>eng</language><publisher>England: BioMed Central</publisher><subject>Arthritis ; Autoimmune diseases ; Cytokines ; Disease ; Inflammation ; Inflammatory diseases ; Kinases ; Ligands ; Lymphocytes ; Neutrophils ; Osteoarthritis ; Pain ; Phosphorylation ; Review</subject><ispartof>Inflammation and Regeneration, 2016-01, Vol.36 (1), p.8-8, Article 8</ispartof><rights>2016. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.</rights><rights>Shiomi et al. 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c517t-52d2d2480eaae2f3067d2849617d0695272160afd32c4cae6ed5192133b9d61d3</citedby><cites>FETCH-LOGICAL-c517t-52d2d2480eaae2f3067d2849617d0695272160afd32c4cae6ed5192133b9d61d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725926/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725926/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29259681$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shiomi, Aoi</creatorcontrib><creatorcontrib>Usui, Takashi</creatorcontrib><creatorcontrib>Mimori, Tsuneyo</creatorcontrib><title>GM-CSF as a therapeutic target in autoimmune diseases</title><title>Inflammation and Regeneration</title><addtitle>Inflamm Regen</addtitle><description>Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been known as a hematopoietic growth factor and immune modulator. Recent studies revealed that GM-CSF also had pro-inflammatory functions and contributed to the pathogenicity of Th17 cells in the development of Th17-mediated autoimmune diseases. GM-CSF inhibition in some animal models of autoimmune diseases showed significant beneficial effects. Therefore, several agents targeting GM-CSF are being developed and are expected to be a useful strategy for the treatment of autoimmune diseases. Particularly, in clinical trials for rheumatoid arthritis (RA) patients, GM-CSF inhibition showed rapid and significant efficacy with no serious side effects. This article summarizes recent findings of GM-CSF and information of clinical trials targeting GM-CSF in autoimmune diseases.</description><subject>Arthritis</subject><subject>Autoimmune diseases</subject><subject>Cytokines</subject><subject>Disease</subject><subject>Inflammation</subject><subject>Inflammatory diseases</subject><subject>Kinases</subject><subject>Ligands</subject><subject>Lymphocytes</subject><subject>Neutrophils</subject><subject>Osteoarthritis</subject><subject>Pain</subject><subject>Phosphorylation</subject><subject>Review</subject><issn>1880-9693</issn><issn>1880-8190</issn><issn>1880-8190</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpdkVFLwzAUhYMoTuZ-gC9S8MWXaG7aJM2LIMNNYeKD-hyy5nbrWNuZtIL_3ozNoSYPuZBzD-fwEXIB7AYgl7chA55yykBSxiCj4oicQZ4zmoNmx_tZS50OyCiEFYtHSCFAn5IB11xomcMZEdNnOn6dJDYkNumW6O0G-64qks76BXZJ1SS279qqrvsGE1cFtAHDOTkp7TrgaP8Oyfvk4W38SGcv06fx_YwWAlRHBXfxZjlDa5GXKZPK8TzTEpRjUguuOEhmS5fyIissSnQxH4c0nWsnwaVDcrfz3fTzGl2BTeft2mx8VVv_ZVpbmb8_TbU0i_bTCBULchkNrvcGvv3oMXSmrkKB67VtsO2DAa00KBEjRunVP-mq7X0T6xkuMiWUAoCogp2q8G0IHstDGGBmy8XsuJjIxWy5GBF3Ln-3OGz8UEi_Af-rhoE</recordid><startdate>20160101</startdate><enddate>20160101</enddate><creator>Shiomi, Aoi</creator><creator>Usui, Takashi</creator><creator>Mimori, Tsuneyo</creator><general>BioMed Central</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160101</creationdate><title>GM-CSF as a therapeutic target in autoimmune diseases</title><author>Shiomi, Aoi ; Usui, Takashi ; Mimori, Tsuneyo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c517t-52d2d2480eaae2f3067d2849617d0695272160afd32c4cae6ed5192133b9d61d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Arthritis</topic><topic>Autoimmune diseases</topic><topic>Cytokines</topic><topic>Disease</topic><topic>Inflammation</topic><topic>Inflammatory diseases</topic><topic>Kinases</topic><topic>Ligands</topic><topic>Lymphocytes</topic><topic>Neutrophils</topic><topic>Osteoarthritis</topic><topic>Pain</topic><topic>Phosphorylation</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shiomi, Aoi</creatorcontrib><creatorcontrib>Usui, Takashi</creatorcontrib><creatorcontrib>Mimori, Tsuneyo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Inflammation and Regeneration</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shiomi, Aoi</au><au>Usui, Takashi</au><au>Mimori, Tsuneyo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>GM-CSF as a therapeutic target in autoimmune diseases</atitle><jtitle>Inflammation and Regeneration</jtitle><addtitle>Inflamm Regen</addtitle><date>2016-01-01</date><risdate>2016</risdate><volume>36</volume><issue>1</issue><spage>8</spage><epage>8</epage><pages>8-8</pages><artnum>8</artnum><issn>1880-9693</issn><issn>1880-8190</issn><eissn>1880-8190</eissn><abstract>Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been known as a hematopoietic growth factor and immune modulator. Recent studies revealed that GM-CSF also had pro-inflammatory functions and contributed to the pathogenicity of Th17 cells in the development of Th17-mediated autoimmune diseases. GM-CSF inhibition in some animal models of autoimmune diseases showed significant beneficial effects. Therefore, several agents targeting GM-CSF are being developed and are expected to be a useful strategy for the treatment of autoimmune diseases. Particularly, in clinical trials for rheumatoid arthritis (RA) patients, GM-CSF inhibition showed rapid and significant efficacy with no serious side effects. This article summarizes recent findings of GM-CSF and information of clinical trials targeting GM-CSF in autoimmune diseases.</abstract><cop>England</cop><pub>BioMed Central</pub><pmid>29259681</pmid><doi>10.1186/s41232-016-0014-5</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1880-9693 |
| ispartof | Inflammation and Regeneration, 2016-01, Vol.36 (1), p.8-8, Article 8 |
| issn | 1880-9693 1880-8190 1880-8190 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5725926 |
| source | DOAJ Directory of Open Access Journals; PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Arthritis Autoimmune diseases Cytokines Disease Inflammation Inflammatory diseases Kinases Ligands Lymphocytes Neutrophils Osteoarthritis Pain Phosphorylation Review |
| title | GM-CSF as a therapeutic target in autoimmune diseases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T01%3A17%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=GM-CSF%20as%20a%20therapeutic%20target%20in%20autoimmune%20diseases&rft.jtitle=Inflammation%20and%20Regeneration&rft.au=Shiomi,%20Aoi&rft.date=2016-01-01&rft.volume=36&rft.issue=1&rft.spage=8&rft.epage=8&rft.pages=8-8&rft.artnum=8&rft.issn=1880-9693&rft.eissn=1880-8190&rft_id=info:doi/10.1186/s41232-016-0014-5&rft_dat=%3Cproquest_pubme%3E1979175480%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2547577111&rft_id=info:pmid/29259681&rfr_iscdi=true |